<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745730</url>
  </required_header>
  <id_info>
    <org_study_id>REF-ICE-2421</org_study_id>
    <nct_id>NCT02745730</nct_id>
  </id_info>
  <brief_title>RS-fMRI to Nutrient Shakes</brief_title>
  <official_title>Resting State Functional Magnetic Resonance Imaging of Human Brain Responses to Nutrient Shake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unilever R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resting state functional magnetic resonance imaging (rsfMRl) of the brain is used to measure
      pleasantness after consumption of four different milkshakes with added sugars or sweeteners.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The central role of the brain in regulating food intake and steering feeding behaviour is
      increasingly recognized. It is currently well accepted that the brain is the target organ to
      measure the effects of pleasantness and energy homeostasis in order to change feeding
      behaviour to reduce the rising prevalence of obesity. The effects of food on the brain are
      multiple and complex. In addition to primary aspects of food such as taste, texture, looks
      and smell, secondary aspects such as energy regulation are as much important in the entire
      &quot;eating experience&quot;. Resting state functional connectivity in the brain can be assessed by
      the analysis of low-frequency fluctuations present in the blood-oxygenation-level-dependent
      (BOLD) signal in functional magnetic resonance imaging (fMRI). Investigators will use resting
      state functional magnetic resonance imaging (rsfMRl) to detect changes in connectivity in the
      default mode and salience network after consumption of four different milkshakes with added
      sugars or sweeteners.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the connectivity in the default mode and salience network: glucose and fructose vs. sucralose and allulose.</measure>
    <time_frame>Six minutes before (baseline) and 12 minutes after (response) test product intake</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2. Change from baseline in the connectivity in the default mode and salience network: glucose vs. fructose.</measure>
    <time_frame>Six minutes before (baseline) and 12 minutes after (response) test product intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Change from baseline in the connectivity in the default mode and salience network: allulose vs. sucralose.</measure>
    <time_frame>Six minutes before (baseline) and 12 minutes after (response) test product intake</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>4. Change from baseline in the connectivity in the default mode and salience network: glucose vs allulose; glucose vs sucralose; fructose vs sucralose and fructose vs allulose.</measure>
    <time_frame>Six minutes before (baseline) and 12 minutes after (response) test product intake</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in the BOLD signal</measure>
    <time_frame>Six minutes before (baseline) and 12 minutes after (response) test product intake</time_frame>
    <description>Using whole brain approach as well as seed based (hypothalamus, prefrontal cortex, nucleus accumbens, Ventral Tegmental Area, Amygdala).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pleasure</condition>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Shake sweetened with glucose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fructose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Shake sweetened with fructose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sucralose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shake sweetened with sucralose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shake sweetened with allulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <arm_group_label>Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fructose</intervention_name>
    <arm_group_label>Fructose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sucralose</intervention_name>
    <arm_group_label>Sucralose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Allulose</intervention_name>
    <arm_group_label>Allulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Age between 18 and 25 years

          -  BMI between 20 and 23 kg/m2

          -  Weight above 70 kg

          -  Length between 170 and 190 centimetres

        Exclusion Criteria:

          -  Diabetes or history of other disturbances of glucose metabolism (eg impaired glucose
             tolerance, hypoglycaemia).

          -  Any genetic or psychiatric disease (e.g. fragile X syndrome, major depression)
             affecting brain

          -  Any know food allergy or intolerance

          -  Any significant chronic disease

          -  Renal or hepatic disease

          -  Recent weight changes or attempts to lose weight (&gt; 3 kg weight gain or loss, within
             the last 3 months)

          -  Smoking (current or last 6 months)

          -  Alcohol consumption of more than 21 units per week or use of recreational drugs at
             present or in the last year

          -  Recent blood donation (within the last 2 months)

          -  Recent participation in other biomedical research projects (within the last 3 months),
             participation in 3 or more biomedical research projects in one year

          -  Contra-indication to MRI scanning:

               -  Claustrophobia

               -  Pacemakers and defibrillators

               -  Nerve stimulators

               -  Intracranial clips

               -  intraorbital or intraocular metallic fragments

               -  Cochlear implants

               -  Ferromagnetic implants
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeroen van der Grond, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

